Browsing by Author "Campos, Durval"
Now showing 1 - 3 of 3
Results Per Page
Sort Options
Item Latin-American guidelines for opioid use in chronic nononcologic pain.(Future Medicine, 2017) Lara, Argelia; Aguayo, Carlos; Amescua, César; Santos, João; Berenguel, María; Bonilla, Patricia; Campos, Durval; Flores, José; Guerrero, Carlos; Guillén, María; Hernández, John; Hernández, Andrés; Jreige, Aziza; Lech, Osvandré; Macías, Jacqueline; Ramírez, Gerardo; Rangel, Edwin; Rico, María; Sempértegui, ManuelAIM: Latin-American experts in the use of opioids in patients with chronic nononcologic pain (CNOP) have updated existing recommendations to current Latin-American reality. METHODS: Several key opinion leaders from Latin America participated in a face-to-face meeting in Guatemala (April 2015) to discuss the use of opioids in CNOP. Subgroups of experts worked on specific topics, reviewed the literature and shaped the final manuscript. RESULTS: The expert panel developed guidelines taking into consideration the utility of both opioid and nonopioid analgesics and factors pertaining to their efficacy, safety, adherence, administration and risks for abuse/addiction. CONCLUSION: Latin-American guidelines for the use of opioids in CNOP should improve pain relief and patients' quality of life by increasing access to these effective agents.Item The role of tramadol in pain management in Latin America: a report by the change pain latin america advisory panel.(Taylor & Francis Online, 2017) Santos, Joao; Lech, Osvandre; Campos, Durval; Rico, Maria; Hernandez, John; Colimon, Frantz; Guerrero, Carlos; Sempertegui, Manuel; Lara, Argelia; Flores, Jose; Amescua, César; Guillen, Maria; Berenguel, Maria; Jreige, Aziza; Bonilla, PatriciaOBJECTIVE: Change Pain Latin America (CPLA) was created to enhance chronic pain understanding and develop pain management improving strategies in this region. During its seventh meeting (August 2016), the main objective was to discuss tramadol's role in treating pain in Latin America. Furthermore, potential pain management consequences were considered, if tramadol was to become more stringently controlled. METHODS: Key topics discussed were: main indications for prescribing tramadol, its pharmacological characteristics, safety and tolerability, effects of restrictions on its availability and use, and consequent impact on pain care quality. RESULTS: The experts agreed that tramadol is used to treat a wide spectrum of non-oncological pain conditions (e.g. post-surgical, musculoskeletal, post-traumatic, neuropathic, fibromyalgia), as well as cancer pain. Its relevance when treating special patient groups (e.g. the elderly) is recognized. The main reasons for tramadol's high significance as a treatment option are: its broad efficacy, an inconspicuous safety profile and its availability, considering that access to strong analgesics - mainly controlled drugs (classical opioids) - is highly restricted in some countries. The CPLA also agreed that tramadol is well tolerated, without the safety issues associated with long-term nonsteroidal anti-inflammatory drug (NSAID) use, with fewer opioid-like side effects than classical opioids and lower abuse risk. CONCLUSIONS: In Latin America, tramadol is a valuable and frequently used medication for treating moderate to severe pain. More stringent regulations would have significant impact on its availability, especially for outpatients. This could cause regression to older and frequently inadequate pain management methods, resulting in unnecessary suffering for many Latin American patients.Item Use of Opioids in Latin America: The Need of an Evidence-Based Change.(American Academy of Pain Medicine, 2016) Rico, Antonieta; Campos, Durval; Jreige, Aziza; Colimon, Frantz; lara, Argelia; Flores, José; Amescua-García, César; Guillén, María; Bonilla, Patricia; Lech, Osvandré; Hernández-Castro, John; Guerrero, Carlos; Delgado, William; Sempértegui, Manuel; Berenguel, María; Santos, Joao; Pérez, ConcepciónOBJECTIVE: The subject of this publication has been focused on local considerations for facilitating regional best practice, including identifying and uniformly adopting the most relevant international guidelines on opioid use (OU) in chronic pain management. DESIGN AND SETTING: The Change Pain Latin America (CPLA) Advisory Panel conducted a comprehensive, robust, and critical analysis of published national and international reviews and guidelines of OU, considering those most appropriate for Latin America. METHODS: A PubMed search was conducted using the terms "opioid," "chronic," and "pain" and then refined using the filters "practice guidelines" and "within the last 5 years" (2007-2012). Once the publications were identified, they were selected using five key criteria: "Evidence based," "Comprehensive," "From a well-recognized source," "Current publications," and "Based on best practice" and then critically analyzed considering 10 key criteria for determining the most relevant guidelines to be applied in Latin America. RESULTS: The initial PubMed search identified 177 reviews and guidelines, which was reduced to 16 articles using the five preliminary criteria. After a secondary analysis according to the 10 key criteria specific to OU in Latin America, 10 publications were selected for critical review and discussion. CONCLUSIONS: The CPLA advisory panel considered the "Safe and effective use of opioids for chronic non-cancer pain" (published in 2010 by the NOUGG of Canada) to be valid, relevant to Latin America, practical, evidence-based, concise, unambiguous, and sufficiently educational to provide clear instruction on OU and pain management and, thus, recommended for uniform adoption across the Latin America region.